PHAS · Phasebio Pharmaceuticals Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $208.0K | $117.0K | - | $335.0K | $10.34M | $0 | - | $0 | $0 | $320.0K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $20.94M | $14.34M | - | $25.07M | $27.37M | $22.32M | - | $17.42M | $20.86M | $11.45M |
| SG&A | $4.58M | $4.01M | - | $3.85M | $4.03M | $3.33M | - | $3.08M | $3.24M | $3.16M |
| Total Operating Expenses | $25.52M | $18.34M | - | $28.91M | $31.39M | $25.65M | - | $20.49M | $24.10M | $14.61M |
| D&A | $600.0K | $601.0K | - | $100.0K | $100.0K | $474.0K | - | - | - | $54.0K |
| Operating Income | ($25.31M) | ($18.23M) | - | ($28.58M) | ($21.05M) | ($25.65M) | - | ($20.49M) | ($24.10M) | ($14.29M) |
| Interest Expense | $116.0K | $148.0K | - | $222.0K | $254.0K | $285.0K | - | $362.0K | $379.0K | $378.0K |
| Income Tax | $0 | - | - | $0 | $1.60M | - | - | - | - | - |
| Net Income | ($16.66M) | ($11.14M) | - | ($31.92M) | ($28.68M) | ($27.36M) | - | ($25.14M) | ($28.14M) | ($14.90M) |
| EPS - Basic | ($0.34) | ($0.23) | - | ($0.66) | ($0.98) | - | - | - | - | - |
| EPS - Diluted | ($0.34) | ($0.87) | - | ($0.66) | ($0.60) | - | - | - | - | - |
Balance Sheet
| Line item | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.80M | $18.69M | $41.80M | $56.36M | $64.46M | $76.96M | $28.12M | $39.35M | $53.02M | $59.44M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $6.32M | $6.78M | $12.57M | $8.52M | $2.96M | $5.90M | $3.67M | $2.12M | $6.97M | $1.92M |
| Current Assets | $11.56M | $27.57M | $48.78M | $65.24M | $88.50M | $88.16M | $40.15M | $49.95M | $63.74M | $72.54M |
| Total Assets | $22.17M | $38.66M | $60.54M | $77.72M | $100.64M | $100.82M | $50.36M | $58.21M | $70.81M | $76.86M |
| Current Liabilities | $24.68M | $21.69M | $27.88M | $21.46M | $16.17M | $16.67M | $14.96M | $11.37M | $17.80M | $7.50M |
| Long-term Debt | $0 | $0 | $1.36M | $2.72M | $4.07M | $5.42M | $6.77M | $8.12M | $9.77M | $11.06M |
| Total Liabilities | $139.56M | $141.06M | $153.57M | $128.05M | $119.81M | $92.41M | $75.56M | $53.85M | $44.42M | $23.37M |
| Stockholders' Equity | ($117.40M) | ($102.39M) | ($93.03M) | ($50.33M) | ($19.18M) | $8.41M | ($25.20M) | $4.35M | $26.39M | $53.49M |
| Retained Earnings | ($419.60M) | ($402.94M) | ($391.79M) | ($348.68M) | ($316.76M) | ($288.08M) | ($260.72M) | ($230.35M) | ($205.21M) | ($177.06M) |
Cash Flow
| Line item | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | ($22.88M) | - | - | - | ($10.20M) | - | - | - | ($23.83M) |
| Investing Cash Flow | - | ($49.0K) | - | - | - | ($133.0K) | - | - | - | ($658.0K) |
| Financing Cash Flow | - | ($179.0K) | - | - | - | $59.17M | - | - | - | $9.90M |
| CapEx | - | $49.0K | - | - | - | $133.0K | - | - | - | $558.0K |
| Free Cash Flow | - | ($22.93M) | - | - | - | ($10.33M) | - | - | - | ($24.39M) |
Ratios
| Metric | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -12169.2% | -15579.5% | - | -8530.1% | -203.6% | - | - | - | - | -4465.0% |
| EBITDA margin | -11880.8% | -15065.8% | - | -8500.3% | -202.7% | - | - | - | - | -4448.1% |
| Net margin | -8012.0% | -9522.2% | - | -9529.6% | -277.4% | - | - | - | - | -4657.8% |
| Free cash flow margin | - | -19600.9% | - | - | - | - | - | - | - | -7620.3% |
| FCF / Net income | - | 2.06 | - | - | - | 0.38 | - | - | - | 1.64 |
| R&D / Revenue | 10066.8% | 12253.0% | - | 7482.4% | 264.7% | - | - | - | - | 3577.8% |
| SG&A / Revenue | 2202.4% | 3426.5% | - | 1147.8% | 38.9% | - | - | - | - | 987.2% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -75.2% | -28.8% | - | -41.1% | -28.5% | -27.1% | - | -43.2% | -39.7% | -19.4% |
| Return on equity | 14.2% | 10.9% | - | 63.4% | 149.6% | -325.3% | - | -577.7% | -106.6% | -27.9% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.47 | 1.27 | 1.75 | 3.04 | 5.47 | 5.29 | 2.68 | 4.39 | 3.58 | 9.68 |
| Quick ratio | 0.47 | 1.27 | 1.75 | 3.04 | 5.47 | 5.29 | 2.68 | 4.39 | 3.58 | 9.68 |
| Cash ratio | 0.32 | 0.86 | 1.50 | 2.63 | 3.99 | 4.62 | 1.88 | 3.46 | 2.98 | 7.93 |
| Leverage | ||||||||||
| Debt / Equity | 0.00 | 0.00 | -0.01 | -0.05 | -0.21 | 0.64 | -0.27 | 1.87 | 0.37 | 0.21 |
| Debt / Assets | 0.00 | 0.00 | 0.02 | 0.03 | 0.04 | 0.05 | 0.13 | 0.14 | 0.14 | 0.14 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -218.2x | -123.2x | - | -128.7x | -82.9x | -90.0x | - | -56.6x | -63.6x | -37.8x |
| Equity multiplier | -0.19 | -0.38 | -0.65 | -1.54 | -5.25 | 11.99 | -2.00 | 13.37 | 2.68 | 1.44 |
| Liabilities / Assets | 6.30 | 3.65 | 2.54 | 1.65 | 1.19 | 0.92 | 1.50 | 0.93 | 0.63 | 0.30 |
| Efficiency | ||||||||||
| Asset turnover | 0.01 | 0.00 | - | 0.00 | 0.10 | 0.00 | - | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -98.0% | - | - | - | - | -100.0% | - | -100.0% | -100.0% | -51.0% |
| Revenue CAGR (3y) | -33.4% | -43.6% | - | -6.6% | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -20.2% | 28.9% | - | -39.4% | 12.6% | -79.5% | - | -76.8% | -154.1% | -93.5% |
| Net income growth (YoY) | 41.9% | 59.3% | - | -27.0% | -1.9% | -83.5% | - | -120.7% | -204.8% | -104.4% |
| EPS growth (YoY) | 43.3% | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | -121.9% | - | - | - | 57.6% | - | - | - | -823.7% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -512.2% | - | -269.2% | - | - | -84.3% | - | -93.9% | -67.7% | 21.3% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$32.46M totalGrant$10.83M · 33.4%
Sublicense Revenue$10.80M · 33.3%
License$10.22M · 31.5%
Development And Regulatory Services$608.0K · 1.9%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing PhaseBio Pharmaceuticals Inc against the 5 most active filers in the same SIC group.